Search Clinical Trials
Thank you for your interest in research at UTMB! Taking part in research is one way to be part of tomorrow’s healthcare discoveries. UTMB is always looking for volunteers just like you so that our researchers can better understand how to prevent, diagnose, and treat diseases. Everyone is needed. Both healthy volunteers and people with health conditions can help us answer important questions that impact the health of our communities. Ready to start searching for a study to be involved with? • Enter a health condition or leave it blank if you are looking to join any study as a healthy volunteer • Enter your gender and age • Click “View Results” • Click on the study titles for information • Click on the “Contact/Details” tab to get information for contacting the study team
Sponsor Condition of Interest |
---|
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
The George Washington University Biostatistics Center
Obstructive Sleep Apnea of Adult
Preeclampsia
Obstetrical Complications
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive
sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a
reduction in the rate of hypertensive disorders of pregnancy. expand
A randomized controlled trial of 1,500 women to assess whether treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy. Type: Interventional Start Date: Aug 2018 |
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer an1
National Cancer Institute (NCI)
Advanced Bladder Carcinoma
Advanced Genitourinary System Carcinoma
Metastatic Bladder Carcinoma
Metastatic Genitourinary System Carcinoma
Stage III Bladder Cancer AJCC v8
This phase II trial studies how well olaparib works in treating patients with bladder
cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects
that has spread to other places in the body (advanced or metastatic) and usually cannot
be cured or controlled with treatment.1 expand
This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Type: Interventional Start Date: Nov 2020 |
Impact of a Telerehabilitation Program With Technology Enhancement on Post-burn Recovery
The University of Texas Medical Branch, Galveston
Burns
The purpose of this study is to examine the effect of participating in a
tele-rehabilitation program after a burn. expand
The purpose of this study is to examine the effect of participating in a tele-rehabilitation program after a burn. Type: Interventional Start Date: Apr 2024 |
Intravesical BCG vs GEMDOCE in NMIBC
ECOG-ACRIN Cancer Research Group
Non-muscle-invasive Bladder Cancer
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC)
patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a
non-inferior event-free survival (EFS) compared to standard treatment with intravesical
BCG. The purpose of this study is to test w1 expand
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high grade non-muscle invasive bladder cancer patients treated with intravesical BCG vs Gemcitabine + Docetaxel. Secondary objectives are as follows: to compare changes in cancer-specific and bladder cancer-specific QOL from baseline to treatment between BCG-naïve high grade NMIBC patients receiving BCG and GEMDOCE, to determine the cystectomy free survival (CFS) of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE, to determine the progression free survival (PFS) of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE, and to determine the safety and toxicity of BCG-naïve high grade NMIBC patients treated with intravesical BCG vs GEMDOCE. Type: Interventional Start Date: Feb 2023 |
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-1
Alliance for Clinical Trials in Oncology
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in
preventing breast cancer from coming back (relapsing) in patients with high risk, HER2
positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a
chemotherapy drug, called DM1. Tra1 expand
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Type: Interventional Start Date: Mar 2021 |
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
M.D. Anderson Cancer Center
Health Knowledge, Attitudes, Practice
Objectives:
This protocol addresses the first phase of a larger project funded by the
Patient-Centered Outcomes Research Institute to help heavy smokers make informed
decisions about lung cancer screening with low-dose computed tomography (CT). A separate
IRB protocol will be submitted for the lar1 expand
Objectives: This protocol addresses the first phase of a larger project funded by the Patient-Centered Outcomes Research Institute to help heavy smokers make informed decisions about lung cancer screening with low-dose computed tomography (CT). A separate IRB protocol will be submitted for the larger, comparative study. In this initial development phase, our prototype patient decision aid will be updated to reflect current guidelines about lung cancer screening. The updated aid will then be pilot-tested in a new sample of patients. In addition, several of the study measures will be refined and further developed in preparation for the larger study. The specific aims of the measures and decision aid development phase of this project are as follows: Update the aid to reflect current screening guidelines and refine the aid via cognitive testing with patients/smokers; and pilot test the updated aid for acceptability with patients/smokers. Modify our current measure of lung cancer knowledge, conduct cognitive testing of the new measure with patients/smokers, and evaluate the reliability of the new measure in a sample patients/smokers. Type: Observational Start Date: Jul 2014 |
Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
The University of Texas Medical Branch, Galveston
Urinary Bladder, Overactive
Urinary Incontinence
Accidental Falls
The goal of this study is to conduct a randomized pilot multi-arm clinical trial
comparing a standard course of physical therapist provided pelvic floor muscle training
(PFMT) to pharmacologic therapy for the treatment of urgency urinary incontinence (UUI)
or Overactive Bladder (OAB) in older women1 expand
The goal of this study is to conduct a randomized pilot multi-arm clinical trial comparing a standard course of physical therapist provided pelvic floor muscle training (PFMT) to pharmacologic therapy for the treatment of urgency urinary incontinence (UUI) or Overactive Bladder (OAB) in older women at high risk of falling. The central hypotheses for this project are i) a randomized pilot multi-arm clinical trial comparing PFMT to drug treatment for UUI or OAB in older women at high risk of falling is feasible; and ii) treatment approach can influence both UI and fall related outcomes in this patient population. The main questions it aims to answer are: 1) Is a multi-arm clinical trial comparing PFMT to drug treatment for UUI or OAB in older women at high risk of falling feasible? and 2) How does treatment approach influence both OAB and fall related outcomes in this patient population? Women (16 per arm) 60 years and older with UUI or OAB who screen positive for high fall risk will be randomized to one of three standard of care treatment arms and followed for six months. The three treatment arms are i) a 12-week structured behaviorally based pelvic floor muscle training (PFMT) intervention administered by physical therapists in the clinic; ii) a 12-week course of the beta-3 agonist, Mirabegron; and iii) a 12-week course of the antimuscarinic, Trospium Chloride. Researchers will compare study feasibility and OAB symptom related outcomes across the three groups to see if a larger clinical trial is warranted. Type: Interventional Start Date: Sep 2023 |
Stroke Thrombectomy and Aneurysm Registry
Medical University of South Carolina
Stroke
Thromboses, Intracranial
Aneurysm, Brain
This international multi-center registry is used to collect existing information and
outcomes for patients undergoing an operation for treatment of injuries to the brain
including the blockage of blood flow to an area of the brain, an abnormal ballooning of
an artery, abnormal tangling of blood ves1 expand
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brain injuries. Additionally, the information is used to compare techniques and devices' effects on technical and clinical outcomes. Type: Observational [Patient Registry] Start Date: Sep 2019 |
Post-Brain Injury Walking and Balance Recovery Program
The University of Texas Medical Branch, Galveston
Acquired Brain Injury
Stroke
Traumatic Brain Injury
The purpose of this study is to test the efficacy of a walking and balance training
program designed to safely challenge and improve walking performance and balance in
relation to walking speed, strength, endurance, and balance after traumatic brain injury
(TBI).
The aim and primary hypothesis of1 expand
The purpose of this study is to test the efficacy of a walking and balance training program designed to safely challenge and improve walking performance and balance in relation to walking speed, strength, endurance, and balance after traumatic brain injury (TBI). The aim and primary hypothesis of this research project is: Aim) Test and implement a new personalized intervention strategy, in addition to usual and customary care at an inpatient rehabilitation clinic, to improve patient outcomes with secondary conditions associated with impaired balance and walking that typically occur post brain injury. After validation of the locomotor Battery of tests, we will implement a personalized training strategy for individuals based on their battery profile. Hypothesis) Individuals training with this individualized protocol will demonstrate improved walking and balance outcomes and those with lesser pre-intervention impairment will improve at a greater rate than those with greater pre-intervention impairment. Type: Interventional Start Date: Aug 2022 |
Low Frequency Ultrasound for Osteoarthritis Healing and Rehabilitation
The University of Texas Medical Branch, Galveston
Osteo Arthritis Knee
Age Related Osteoporosis
Pain
Knee Joint Contracture
The purpose of this study is to determine the safety and effectiveness (how well it
works) of a new experimental ultrasound bath device that uses low frequency ultrasound
(LFU) that may or may not help healing. expand
The purpose of this study is to determine the safety and effectiveness (how well it works) of a new experimental ultrasound bath device that uses low frequency ultrasound (LFU) that may or may not help healing. Type: Interventional Start Date: Jul 2024 |
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
Biodesix, Inc.
Nodule Solitary Pulmonary
Non-small Cell Carcinoma
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical
management of newly identified solid lung nodules assessed as low to moderate risk of
cancer. expand
This study evaluates the how addition of the Nodify XL2 test result impacts the clinical management of newly identified solid lung nodules assessed as low to moderate risk of cancer. Type: Observational Start Date: Dec 2020 |
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Endologix
AAA
AAA - Abdominal Aortic Aneurysm
Prospective, randomized, multi-center study designed to evaluate the outcomes of
commercially available contemporary EVAR in a real-world population. Patients will be
randomized into two device cohorts and compared across the primary endpoints.
Patients will be followed procedurally to discharge,1 expand
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment). Type: Interventional Start Date: Sep 2021 |
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
The University of Texas Medical Branch, Galveston
Spinal Cord Injuries
Urinary Incontinence
The goal of this study is to determine whether administration of sildenafil will decrease
urine leakage in patients with spinal cord injuries. expand
The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries. Type: Interventional Start Date: Jul 2021 |
Cardiogenic Shock Working Group Registry
Tufts Medical Center
Cardiogenic Shock
The Cardiogenic Shock Working Group is a multicenter registry where we collect
de-identified clinical variables from the medical records and follow-up phone calls of
shock patients from multiple institutions and centralize this data to a single registry
for analysis of clinical outcomes. expand
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes. Type: Observational [Patient Registry] Start Date: Dec 2017 |
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary I1
Calliditas Therapeutics AB
IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO®
(delayed-release budesonide capsules) treatment in adult patients with primary IgA
nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in
real-world clinical practice. The main quest1 expand
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done Type: Interventional Start Date: Dec 2024 |
The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and1
The University of Texas Medical Branch, Galveston
Brain Injuries
The aim of this study is to characterize the microbiome of patients undergoing post-acute
residential neurorehabilitation compared to community controls and to determine if a
dietary fiber, Inulin, can create a shift in the microbiome leading to changes in fatigue
and cognition. expand
The aim of this study is to characterize the microbiome of patients undergoing post-acute residential neurorehabilitation compared to community controls and to determine if a dietary fiber, Inulin, can create a shift in the microbiome leading to changes in fatigue and cognition. Type: Interventional Start Date: Mar 2025 |
POLARx Post Approval Study (POLARx PAS)
Boston Scientific Corporation
Paroxysmal Atrial Fibrillation
To collect clinical data on safety, effectiveness and procedural success of Boston
Scientific's Cardiac Cryoablation System (includes all BSC commercially available
POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the
ablation treatment of de novo Atrial Fibrillat1 expand
To collect clinical data on safety, effectiveness and procedural success of Boston Scientific's Cardiac Cryoablation System (includes all BSC commercially available POLARx/POLARx Fit catheters) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of de novo Atrial Fibrillation (AF). Type: Interventional Start Date: Jun 2024 |
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NRG Oncology
Breast Cancer
Cognitive Impairments
This Phase III trial will examine the efficacy of computerized cognitive training methods
on perceived cognitive impairment in breast cancer survivors. expand
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors. Type: Interventional Start Date: Apr 2024 |
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NRG Oncology
Stage III Colon Cancer
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to
patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery
for colon cancer. expand
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer. Type: Interventional Start Date: Mar 2022 |
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
University of Florida
Intracranial Arteriosclerosis
Stroke
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or
ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of
ischemic stroke, intracerebral hemorrhage, or vascular death. expand
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death. Type: Interventional Start Date: Aug 2022 |
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With1
Mitsubishi Tanabe Pharma America Inc.
EPP
XLP
To evaluate the long-term safety and tolerability of oral dersimelagon. expand
To evaluate the long-term safety and tolerability of oral dersimelagon. Type: Interventional Start Date: Aug 2021 |
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoace1
Innoviva Specialty Therapeutics
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam
(SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK)
and safety data to enable the identification of appropriate pediatric dosing regimens for
patients with Acinetobacter baumannii-c1 expand
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections Type: Interventional Start Date: May 2025 |
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
The University of Texas Medical Branch, Galveston
Chronic Subdural Hematoma
The goal of this clinical trial is to test in moderately symptomatic chronic subdural
hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an
alternative to conventional open surgery. The main questions it aims to answer are:
- Compared to open conventional sur1 expand
The goal of this clinical trial is to test in moderately symptomatic chronic subdural hematoma (CSDH) patients if middle meningeal artery embolization (MMAE) can be used as an alternative to conventional open surgery. The main questions it aims to answer are: - Compared to open conventional surgery, does MMAE reduce the need for rescue surgery or deaths? - What is the safety of MMAE and conventional open surgery in these patients? Participants will be asked to: - Share their medical history and undergo physical examinations - Have blood drawn - Have CT scans of the head - Answer questionnaires - Undergo MMAE or conventional open surgery - Provide information about possible adverse events Researchers will compare participants in the MMAE group with those in the conventional open surgery group to see if there is a reduced need for rescue surgery or deaths and evaluate safety. Type: Interventional Start Date: Nov 2024 |
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
Weill Medical College of Cornell University
Advanced Cancer
This is a pilot trial of the effects of spiritual care interventions on spiritual
well-being and readiness to engage in advance care planning (ACP) among black patients
with advanced cancer recruited from outpatient settings to determine the feasibility of
conducting a larger trial of effects of ea1 expand
This is a pilot trial of the effects of spiritual care interventions on spiritual well-being and readiness to engage in advance care planning (ACP) among black patients with advanced cancer recruited from outpatient settings to determine the feasibility of conducting a larger trial of effects of early integration of spiritual care into outpatient oncology care on patient outcomes. Type: Interventional Start Date: Mar 2025 |
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Par1
Novartis Pharmaceuticals
Lupus Nephritis
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.)
ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in
combination with SoC, in adult participants with active LN expand
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN Type: Interventional Start Date: Jul 2022 |
- Previous
- Next